Nykode Therapeutics AS Statistics

Total Valuation

Nykode Therapeutics AS has a market cap or net worth of NOK 971.15 million. The enterprise value is -293.24 million.

Market Cap	971.15M
Enterprise Value	-293.24M

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Nykode Therapeutics AS has 326.55 million shares outstanding. The number of shares has decreased by -14.88% in one year.

Current Share Class	n/a
Shares Outstanding	326.55M
Shares Change (YoY)	-14.88%
Shares Change (QoQ)	-12.18%
Owned by Insiders (%)	15.96%
Owned by Institutions (%)	28.61%
Float	173.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.60
PB Ratio	0.65
P/TBV Ratio	0.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.74
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.32

Financial Position

The company has a current ratio of 7.96, with a Debt / Equity ratio of 0.03.

Current Ratio	7.96
Quick Ratio	7.96
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	-295.98

Financial Efficiency

Return on equity (ROE) is -27.41% and return on invested capital (ROIC) is -26.25%.

Return on Equity (ROE)	-27.41%
Return on Assets (ROA)	-21.69%
Return on Capital (ROIC)	-26.25%
Revenue Per Employee	248,738
Profits Per Employee	-2.13M
Employee Count	173
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -84.30% in the last 52 weeks. The beta is 1.34, so Nykode Therapeutics AS's price volatility has been higher than the market average.

Beta (5Y)	1.34
52-Week Price Change	-84.30%
50-Day Moving Average	3.48
200-Day Moving Average	9.68
Relative Strength Index (RSI)	45.64
Average Volume (20 Days)	2,351,136

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nykode Therapeutics AS had revenue of NOK 46.02 million and -393.85 million in losses. Loss per share was -1.37.

Revenue	46.02M
Gross Profit	46.02M
Operating Income	-626.45M
Pretax Income	-505.25M
Net Income	-393.85M
EBITDA	-618.66M
EBIT	-626.45M
Loss Per Share	-1.37

Full Income Statement

Balance Sheet

The company has 1.31 billion in cash and 47.86 million in debt, giving a net cash position of 1.26 billion or 3.87 per share.

Cash & Cash Equivalents	1.31B
Total Debt	47.86M
Net Cash	1.26B
Net Cash Per Share	3.87
Equity (Book Value)	1.50B
Book Value Per Share	4.60
Working Capital	1.19B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -913.69 million and capital expenditures -1.98 million, giving a free cash flow of -915.67 million.

Operating Cash Flow	-913.69M
Capital Expenditures	-1.98M
Free Cash Flow	-915.67M
FCF Per Share	-2.80

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,361.35%
Pretax Margin	-1,097.99%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Nykode Therapeutics AS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	14.88%
Shareholder Yield	14.88%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on July 7, 2020. It was a forward split with a ratio of 5.

Last Split Date	Jul 7, 2020
Split Type	Forward
Split Ratio	5

Scores

Nykode Therapeutics AS has an Altman Z-Score of 10.35.

Altman Z-Score	10.35
Piotroski F-Score	n/a